Regeneron Pharma wins FDA acceptance for VEGF Trap-Eye review
The FDA has also granted the its request for priority review of its BLA. Under priority review, the target date for an FDA decision on the VEGF Trap-Eye
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.